Get a perfect gift for your loved ones. View Gift Offers
You have probably tried before. Maybe more than once. Different diets, different approaches, different timelines and each time, the weight came back, and the explanation you were given was something like ‘just eat less and move more.’ If that advice was sufficient, you wouldn’t still be looking.
Medical weight loss is different because it starts with a different premise: weight is a complex, chronic, physiological condition not a willpower problem. The GLP-1 medications available today (semaglutide, tirzepatide) represent a genuine turning point in what medicine can offer people who struggle with excess weight. Under physician supervision, with the right metabolic workup and an honest conversation about what the evidence shows, the results can be genuinely life-changing.
Dr. J Anti-Aging Clinic offers medical weight loss programs in Orlando physician-supervised, lab-guided, and designed around your biology, not a script.
Mean Body Weight Lost with Semaglutide 2.4mg + Lifestyle Intervention at 68 Weeks
Mean Body Weight Lost with Tirzepatide 15mg at 72 Weeks vs. 3.1% for Placebo
Reduction in Major Adverse Cardiovascular Events (MACE) with Semaglutide in High-Risk Patients
"I have practiced medicine for over 25 years. I have watched patients fight their weight their entire adult lives trying every diet, every program, every supplement and blame themselves when nothing worked. The truth is that obesity is a complex, chronic disease. It has hormonal drivers, neurological drivers, metabolic drivers. Telling someone to 'eat less and exercise more' when their GLP-1 signaling is dysregulated is like telling someone with hypothyroidism to 'just have more energy.' The GLP-1 medications available today semaglutide, tirzepatide are the most effective pharmacological tools I have seen in my career for weight management. They are not magic; they are most effective when combined with metabolic evaluation, nutritional support, and lifestyle change. And they are not right for everyone. But for the right patient, the results I have seen have been remarkable not just pounds lost, but better blood pressure, better blood sugar, better energy, better sleep, and patients who finally feel like themselves again. My job is to evaluate your individual biology, prescribe appropriately, monitor your response, and have honest conversations about what we can and cannot achieve. That is what physician-supervised weight loss means. I am Dr. J ABIM board-certified, 25+ years of experience, and I will be your actual physician throughout this process."
Decades of research have established that body weight is regulated by a complex system of hormones, neurotransmitters, and feedback loops that actively resist weight loss. When you lose weight through caloric restriction alone, your body responds with compensatory mechanisms: hunger increases (via ghrelin), satiety decreases (via reduced leptin signaling), and metabolic rate drops. These mechanisms are not character flaws they are evolutionary survival responses that work against every conventional diet attempt.
GLP-1 (glucagon-like peptide-1) is an incretin hormone produced naturally in the gut after eating. It signals the brain’s hypothalamus to reduce appetite, signals the pancreas to release insulin in a glucose-dependent manner, and slows gastric emptying to prolong fullness. In people with obesity, GLP-1 signaling is often impaired contributing to the reduced satiety and increased caloric intake that drives weight gain. GLP-1 receptor agonists (GLP-1 RAs) like semaglutide and tirzepatide restore and amplify this physiological signal, addressing the biology of overeating rather than just its behavioral expression.
This is not a shortcut. These medications require consistent use, appropriate dose titration, and lifestyle support to achieve and maintain their full benefit. But they work at the level of root cause which is why the clinical trial results are so different from what diet programs alone have produced.
Semaglutide (Wegovy® / Compounded)
Semaglutide is the most extensively studied GLP-1 receptor agonist for weight management. Administered as a once-weekly subcutaneous injection, it works by activating GLP-1 receptors in the hypothalamus (reducing appetite), slowing gastric emptying (extending satiety), and improving glucose-dependent insulin secretion. The approved weight-loss formulation (Wegovy®) is dosed at 2.4mg weekly after a 16-week dose-escalation protocol to minimize gastrointestinal side effects.
Compounded semaglutide prepared by FDA-registered 503B outsourcing facilities or licensed compounding pharmacies may be offered when the branded formulation is unavailable or cost-prohibitive. Compounded medications are not individually FDA-approved; Dr. J’s practice discloses this clearly and prescribes compounded formulations only through verified licensed pharmacies with appropriate quality standards. Note: As of early 2025, the FDA has signaled tightening regulations on compounded semaglutide as branded drug shortages resolve. Patients will be advised on current regulatory status at consultation.
Tirzepatide (Zepbound® / Compounded)
Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist the first of its class. By activating both incretin receptor pathways simultaneously, tirzepatide produces greater weight loss than GLP-1 agonism alone in head-to-head trials. The SURMOUNT-5 trial (NEJM, 2024) found tirzepatide produced 20.2% mean body weight loss versus 13.7% for semaglutide at 72 weeks in non-diabetic adults with obesity (p<0.001). Tirzepatide is FDA-approved for chronic weight management as Zepbound® at doses of 5, 10, and 15mg weekly.
Mechanism: GLP-1 receptor agonist
Mean Weight Loss: 15% at 68 weeks (STEP-1)
FDA Approval: Wegovy® for chronic weight mgmt
CV Outcome Data: Select trial 20% MACE reduction
Dosing: Once weekly injection
Dose Escalation: 16 weeks to 2.4mg
GI Side Effects: Nausea, vomiting common
Key Consideration: Strongest CV outcome evidence
Mechanism: Dual GIP + GLP-1 agonist
Mean Weight Loss: Loss: 21% at 72 weeks (SURMOUNT-1)
FDA Approval: Zepbound® for chronic weight mgmt
CV Outcome Data: SURPASS-CVOT data; no MACE trial yet (non-diabetic)
Dosing: Once weekly injection
Dose Escalation: 20 weeks to 15mg
GI Side Effects: Similar; slightly less discontinuation
Key Consideration: Greater weight loss efficacy
STEP-1 Limitation: The STEP 1 Extension (Wilding et al. Diabetes Obes Metab 2022, PMID 35441470) found that one year after stopping semaglutide, participants regained approximately two-thirds of the weight lost. Cardiometabolic improvements also partially reversed. This confirms that obesity is a chronic condition requiring ongoing treatment stopping the medication without a long-term maintenance plan is associated with weight regain in most patients.
Lincoff et al. (NEJM, 2023). Landmark phase 3 RCT. N=17,604 non-diabetic adults with BMI ≥27 and established cardiovascular disease. Semaglutide 2.4mg vs. placebo weekly for ~40 months. Primary outcome (MACE cardiovascular death, nonfatal MI, nonfatal stroke): 6.5% semaglutide vs. 8.0% placebo (HR 0.80, 95% CI 0.72–0.90, p<0.001) a 20% relative risk reduction. All-cause mortality: 4.3% vs. 5.2% (HR 0.81). FDA subsequently approved semaglutide 2.4mg for MACE reduction in this population in March 2024. Adverse events leading to discontinuation were twice as common in the semaglutide group (16.6% vs. 8.2%), primarily due to gastrointestinal side effects.
Phase 3b, open-label RCT. N=751 non-diabetic adults with obesity. Tirzepatide (10 or 15mg) vs. semaglutide (1.7 or 2.4mg) weekly for 72 weeks. Primary outcome: mean weight change −20.2% tirzepatide vs. −13.7% semaglutide (p<0.001). Waist circumference: −18.4cm vs. −13.0cm (p<0.001). Tirzepatide participants more likely to achieve ≥10%, ≥15%, ≥20%, and ≥25% weight loss thresholds. GI adverse events causing discontinuation: 2.7% tirzepatide vs. 5.6% semaglutide. This is the first published head-to-head comparison of the two agents for weight loss.
An exploratory DEXA substudy of STEP-1 (N=140) found that semaglutide produced reductions in total fat mass (−19.3%) and regional visceral fat (−27.4%) highly favorable. However, total lean body mass also decreased (−9.7%). Overall, the lean body mass proportion relative to total mass increased (+3.0 percentage points), and the lean-to-fat mass ratio improved, suggesting the body composition shift was net positive.
Separate analyses (including a 2025 Cell Metabolism commentary on STEP-1 data) noted that lean mass comprised approximately 40–45% of total weight lost in some analyses higher than the approximately 25% typically seen with diet-induced weight loss. Whether this reflects loss of skeletal muscle (vs. fat-free mass from other tissue, including adipose-associated lean mass) is actively debated in the literature. Case series data (PMC12536186) suggest that structured resistance training (3–5 days/week) and adequate protein intake (≥1.6g/kg lean body mass/day) can substantially reduce or eliminate lean mass loss during GLP-1 treatment. Dr. J's protocol includes body composition guidance and referral for resistance training for all GLP-1 patients, particularly those over 50 where sarcopenia risk is elevated.
A physician-supervised weight loss program is different from a subscription medication service. Here is what every patient receives at Dr. J Anti-Aging Clinic.
Step 1: Comprehensive Metabolic Lab Panel
Before any prescription is written, Dr. J orders a comprehensive baseline metabolic evaluation CBC, CMP, HbA1c, fasting glucose, fasting insulin, thyroid panel (TSH, free T3, free T4), lipid panel, hepatic function, inflammatory markers (hsCRP), and hormonal evaluation as indicated. Weight gain is frequently driven or worsened by hypothyroidism, insulin resistance, cortisol dysregulation, or hormonal decline. These factors are identified and addressed, not ignored.
Step 2: Physician Consultation & GLP-1 Candidacy Assessment
Dr. J reviews your lab results, medical history, medications, and weight history in person. Contraindications are assessed carefully (see below). A personalized treatment plan is developed including medication selection (semaglutide vs. tirzepatide), starting dose, titration schedule, and monitoring plan. Patients with personal or family history of MEN2 or medullary thyroid cancer are NOT candidates for GLP-1 treatment.
Step 3: Dose Titration & Monitoring
GLP-1 medications require gradual dose escalation to minimize gastrointestinal side effects. Patients are monitored through regular check-ins in-person or via telemedicine with dose adjustments based on tolerance and response. Labs are repeated at appropriate intervals to monitor hepatic function, blood glucose, and other metabolic markers.
Step 4: Lifestyle Integration Protein, Resistance Training, and Nutrition
Medication is most effective when combined with behavioral change. Dr. J’s team provides guidance on protein intake targets, resistance training recommendations to preserve lean mass, and nutritional strategies that complement GLP-1’s mechanism. Patients who maximize lifestyle support during treatment tend to sustain better results long-term if and when they transition off medication.
Step 5: Long-Term Maintenance Planning
Because obesity is a chronic condition and weight regain after stopping GLP-1 medications is well-documented in the literature, maintenance planning is discussed from the first appointment. Options include continued low-dose GLP-1 maintenance, structured step-down protocols, metabolic optimization of thyroid and hormonal factors, and for qualifying patients combination strategies with other metabolic therapies available through the practice.
Dr. J’s practice does not minimize GLP-1 side effects or contraindications. The following is accurate, complete information consistent with FDA labeling and published trial data.
Common Side Effects (Mild to Moderate, Usually Transient)
Gastrointestinal side effects are the most common reason patients reduce dose or discontinue. They are most prominent during dose escalation and typically improve at stable doses.
Serious Side Effects (Rare Require Medical Attention)
• Personal or family history of Medullary Thyroid Carcinoma (MTC)
• Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Known hypersensitivity to semaglutide or tirzepatide
• Pregnancy or breastfeeding (GLP-1 RAs should be discontinued at least 2 months before planned pregnancy)
• History of pancreatitis (acute or chronic)
• Pre-existing gallbladder disease or active cholelithiasis
• Severe gastrointestinal disease (gastroparesis, inflammatory bowel disease)
• Patients on insulin or sulfonylureas (hypoglycemia risk; dose adjustment required)
• Patients with pre-existing cardiac arrhythmia
• Renal or hepatic impairment (requires dose consideration and closer monitoring)
• Patients with active eating disorders GLP-1’s appetite suppression is not appropriate for patients with anorexia, restrictive eating, or active bulimia
All candidacy determinations are made by Dr. J following review of your full medical history and lab results. No patient is prescribed GLP-1 medications without this evaluation.
Weight Regain After Stopping Treatment:
The STEP 1 Extension (PMID 35441470) documented ~two-thirds weight regain within one year of stopping semaglutide. This has significant implications for how patients approach treatment as a chronic disease management strategy rather than a temporary course. Newer real-world data (Epic Research, 2025) suggests more heterogeneous outcomes: at 24 months post-cessation, 56% of semaglutide patients had maintained or continued losing weight. The picture is more complex than either ‘you’ll regain everything’ or ‘most maintain their loss’ and individual response appears to vary substantially.
Lean Mass and Muscle Loss:
Approximately 40–45% of total weight lost during GLP-1 treatment may represent lean mass in some analyses, compared to ~25% typically expected during diet-induced weight loss. Whether this reflects skeletal muscle loss (which would be clinically concerning) or fat-free mass associated with excess adipose tissue (which would be less concerning) is actively debated. Resistance training and adequate protein appear to substantially mitigate lean mass loss, but large RCT data on this question is not yet published.
Long-Term Safety Beyond 5 Years:
GLP-1 medications at obesity doses have been in widespread use for approximately 3–4 years. SELECT provides strong cardiovascular safety data in a high-risk population over ~40 months. Data on thyroid cancer risk, pancreatic cancer risk, and very long-term outcomes in the broader population is still accumulating. Currently, no elevated cancer signal has been observed in trial data, and animal model concerns (rodent-specific thyroid C-cell findings) have not translated to human data but surveillance is ongoing.
Compounded Semaglutide Regulatory Status:
The FDA has indicated that as brand shortages resolve, compounded semaglutide formulations will face stricter regulatory scrutiny. Patients currently on compounded formulations should be aware that availability may change. Dr. J’s practice will keep patients informed of the current status and transition pathways to branded formulations when appropriate.
Appropriate Candidates
NOT Appropriate Candidates
Comprehensive metabolic, hormonal, and thyroid labs ordered and reviewed. Medical history assessment. GLP-1 candidacy confirmed. Medication selected and prescription initiated. Starting dose begins 0.25mg weekly for semaglutide, 2.5mg weekly for tirzepatide.
Dose increases every 4 weeks per protocol. Most patients experience the highest GI side effect burden during this phase managed with dietary adjustments (eating smaller portions, avoiding high-fat and spicy foods, staying hydrated). Telehealth check-in at week 4 to review tolerance and adjust plan.
Most patients are at or approaching their target maintenance dose by week 12–16. Weight loss becomes more substantial as effective dosing is achieved. Body composition guidance is reinforced protein targets, resistance training schedule. Progress is documented and results discussed.
In-person visit with repeat relevant labs as indicated. Weight, waist circumference, blood pressure, and metabolic markers documented. Medication adjusted if needed. Long-term maintenance plan discussion begins.
Yes and no. Ozempic®, Wegovy®, and compounded semaglutide all contain the same active molecule semaglutide, a GLP-1 receptor agonist. Ozempic® is FDA-approved for type 2 diabetes management at doses up to 2.0mg weekly. Wegovy® is the same molecule approved at 2.4mg weekly specifically for chronic weight management in adults with obesity or overweight with comorbidities. Using Ozempic® for weight loss is technically off-label, though very widely practiced. Dr. J prescribes the formulation appropriate to your clinical situation with full transparent discussion of FDA approval status.
The clinical evidence indicates that most patients who stop GLP-1 medications regain a significant portion of the weight they lost the STEP 1 extension found approximately two-thirds regain within one year of stopping. This reflects the chronic nature of obesity as a disease, not a failure of the medication or the patient. Some patients achieve metabolic improvements during treatment (blood pressure normalization, prediabetes reversal, lifestyle habit establishment) that allow for a reduced-dose maintenance approach or a structured taper. This is discussed individually there is no single answer, and Dr. J will give you an honest assessment based on your specific situation.
Patients with a BMI between 27–30 with a weight-related health condition (e.g., elevated blood pressure, prediabetes, elevated triglycerides) meet clinical candidacy criteria for GLP-1 therapy. Patients with a BMI under 27 are not candidates under current FDA labeling, and this practice does not prescribe GLP-1 medications for purely aesthetic weight loss in patients without metabolic indication. The consultation determines appropriateness.
Online GLP-1 prescribers (telehealth weight loss services) typically operate without in-person evaluation, without comprehensive metabolic lab review prior to prescription, and without physician continuity you may see a different provider at each visit, or none at all beyond a form review. Dr. J is your actual physician. Your labs are reviewed by Dr. J. Your dose adjustments are made by Dr. J. Your long-term health is the goal, not prescription volume. For patients with complex medical histories, this distinction matters significantly.
Coverage varies substantially by plan, employer, and state. Wegovy® is covered by some commercial insurance plans and some Medicare Advantage plans, particularly following the SELECT trial data and the expanded FDA indication for cardiovascular risk reduction in March 2024. Tirzepatide (Zepbound®) coverage is expanding. Compounded semaglutide is typically not covered by insurance. Dr. J’s office can provide a Superbill for potential out-of-network reimbursement. We recommend contacting your insurance provider directly to verify coverage prior to your consultation.
This is a legitimate concern raised in the literature and one Dr. J discusses with all patients. Trial data shows that lean body mass is reduced during GLP-1-induced weight loss, with some analyses suggesting lean mass comprises a higher-than-expected proportion of total weight lost. However, the overall body composition shift (less total fat, improved lean-to-fat ratio) appears net positive. The evidence-based mitigation strategy: structured resistance training (3–5 days per week) and adequate dietary protein (1.6g/kg lean body mass/day). Patients who implement these strategies show substantially better lean mass preservation. Body composition assessment can be incorporated into your monitoring plan.
Dr. J Anti-Aging Clinic is based in 7300 Sand Lake Commons Blvd Ste 227 L, Orlando, FL 32819. Our medical weight loss program is available in-person for Central Florida patients and via telehealth for qualified patients across Florida. We serve communities throughout the greater Orlando metro and a ~100-mile radius including:
Orlando · Dr. Phillips · Sand Lake · Winter Park · Kissimmee · St. Cloud · Clermont · Windermere · Ocoee · Winter Garden · Sanford · Lake Mary · Altamonte Springs · Longwood · Casselberry · Maitland · Deltona · Daytona Beach · Ocala · Gainesville · Lakeland · Tampa · Melbourne · Titusville · Leesburg · The Villages
The J-Glow™ is available at Dr. J Anti-Aging Clinic in Orlando, FL. Your first consultation is complimentary. Dr. J will assess your skin, explain exactly what the treatment involves, and give you an honest picture of what results are realistically achievable for your specific skin. No pressure, no sales script.
Semaglutide (Wegovy®) and tirzepatide (Zepbound®) are FDA-approved for chronic weight management in adults meeting clinical criteria. Compounded semaglutide formulations, when offered, are not individually FDA-approved. The use of Ozempic® (semaglutide 2.0mg) for weight management is off-label. All prescribing decisions at Dr. J Anti-Aging Clinic are made by Dr. J following comprehensive medical evaluation and informed consent. Individual results vary. This page is for educational purposes and does not constitute personalized medical advice. Patients are encouraged to discuss all medications and health conditions with their physician. This page was reviewed for clinical accuracy in March 2026. Evidence cited includes PMID 33567185 (STEP-1), PMID 37952131 (SELECT), PMID 35441470 (STEP-1 Extension), SURMOUNT-5 (NCT05822830, NEJM 2024).
Learn the latest techniques in medical anti-aging. Offer extra services to your existing patients and also get many new patients looking for these services. Increase your practice revenue and help patients achieve and improve their lifestyle. Become part of nations leading anti-aging providers.
